Lilly's Latest Findings Unveil Breakthrough in Psoriatic Arthritis and Obesity Combination Therapy Recent data from Lilly shows that combining Taltz and Zepbound significantly improves outcomes for patients with psoriatic arthritis and obesity.

Lilly's Latest Findings Unveil Breakthrough in Psoriatic Arthritis and Obesity Combination Therapy #USA #Indianapolis #Zepbound #Psoriatic_Arthritis #Taltz

Sun Pharma's ILUMYA Receives FDA Review for Psoriatic Arthritis Treatment Expansion Sun Pharma has announced that the FDA has accepted its application for ILUMYA, aiming to expand treatment options for adults with psoriatic arthritis, adding to its existing psoriasis indications.

Sun Pharma's ILUMYA Receives FDA Review for Psoriatic Arthritis Treatment Expansion #USA #Princeton #ILUMYA #Sun_Pharma #Psoriatic_Arthritis

BIMZELX® Outperforms SKYRIZI® in Groundbreaking Psoriatic Arthritis Study UCB's BIMZELX® (bimekizumab) demonstrates superior efficacy compared to SKYRIZI® (risankizumab) in reducing disease activity in patients with active psoriatic arthritis.

BIMZELX® Outperforms SKYRIZI® in Groundbreaking Psoriatic Arthritis Study #United_States #Atlanta #BIMZELX #Skyrizi #Psoriatic_Arthritis

Exploring Patient-Centric Research Approaches: Insights from Psoriatic Arthritis Cases Join the seminar on March 18, 2026, to learn effective patient-centric research strategies focusing on psoriatic arthritis insights.

Exploring Patient-Centric Research Approaches: Insights from Psoriatic Arthritis Cases #Japan #Tokyo #Psoriatic_Arthritis #Asmarq #patient-centric

First #ARCH_ArLAR in 2026 💫

🚀 Congratulations to Pr. Wafa Hamdi & team on this new publication from the ARCH TACTIC #Psoriatic_Arthritis database!

🔗 doi: 10.1007/s10067-026-07925-2

Combining Lilly's Taltz and Zepbound Shows Promising Results for Psoriatic Arthritis and Obesity The TOGETHER-PsA trial reveals that using Taltz and Zepbound together significantly improves outcomes for patients suffering from psoriatic arthritis and obesity.

Combining Lilly's Taltz and Zepbound Shows Promising Results for Psoriatic Arthritis and Obesity #United_States #Indianapolis #Zepbound #Psoriatic_Arthritis #Taltz

Long-term Study Solidifies TREMFYA® as Leading Treatment for Psoriatic Arthritis New findings affirm TREMFYA® (guselkumab) as the leading IL-23 inhibitor in preventing joint damage in active psoriatic arthritis, with impressive long-term efficacy.

Long-term Study Solidifies TREMFYA® as Leading Treatment for Psoriatic Arthritis #United_States #New_York #TREMFYA® #guselkumab #Psoriatic_Arthritis

On World Arthritis Day 2025, the LSR is raising #arthritis awareness by talking directly to the patients

Check out this snapshot of our social media and TV campaign 📷
#rheumatoid_arthritis, #psoriatic_arthritis & #juvenile_arthritis #gout #fibromyalgia & more #wad2025

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment TREMFYA® is now FDA approved for the treatment of pediatric patients with plaque psoriasis and active psoriatic arthritis, offering new hope for children with these conditions.

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment #United_States #TREMFYA #pediatric_psoriasis #Horsham #Psoriatic_Arthritis

Understanding #Psoriatic_Arthritis
An awareness campaign collaboration between the LSR & Mersaco

#World_Arthritis_Day
#Ask_your_rheumatologist
#Rheumatology

Johnson & Johnson Submits FDA Application for TREMFYA® to Enhance Psoriatic Arthritis Treatment Efficacy Johnson & Johnson has submitted an application to the FDA to enhance TREMFYA®'s label with new evidence, proving its efficacy in combating joint damage from psoriatic arthritis.

Johnson & Johnson Submits FDA Application for TREMFYA® to Enhance Psoriatic Arthritis Treatment Efficacy #United_States #TREMFYA® #Johnson_&_Johnson #Horsham #Psoriatic_Arthritis

❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?

🅰️ Yes

🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy

Promising Three-Year Results of BIMZELX® in Treating Psoriatic Arthritis and Axial Spondyloarthritis Unveiled at EULAR 2025 Recent data from UCB's BIMZELX® show sustained efficacy in managing psoriatic arthritis and axial spondyloarthritis over three years, highlighting its therapeutic potential.

Promising Three-Year Results of BIMZELX® in Treating Psoriatic Arthritis and Axial Spondyloarthritis Unveiled at EULAR 2025 #None #Barcelona #BIMZELX #Psoriatic_Arthritis #Axial_Spondyloarthritis

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment Discover how Johnson & Johnson's TREMFYA® offers significant benefits in treating active psoriatic arthritis, showcasing remarkable results in the APEX study.

Johnson & Johnson's TREMFYA® Demonstrates Efficacy in Psoriatic Arthritis Treatment #United_States #New_Brunswick #TREMFYA #guselkumab #Psoriatic_Arthritis

New Study Reveals TREMFYA® as First-Choice Treatment for Psoriatic Arthritis Johnson & Johnson announces TREMFYA® as the first IL-23 inhibitor effective in reducing psoriatic arthritis symptoms and preventing damage.

New Study Reveals TREMFYA® as First-Choice Treatment for Psoriatic Arthritis #Johnson_&_Johnson #TREMFYA #Psoriatic_Arthritis

Major Transformations in the Psoriatic Arthritis Market Driven by Biosimilar Adoption and New Treatments The psoriatic arthritis market is experiencing significant changes due to the rise of biosimilars and innovative treatments, enhancing patient access and options.

Major Transformations in the Psoriatic Arthritis Market Driven by Biosimilar Adoption and New Treatments #United_States #Las_Vegas #DelveInsight #Biosimilars #Psoriatic_Arthritis